In 2019 Prosol announced the promising result of a first study on the role of dietary nucleotides (Ribodiet®) in Alzheimer disease. Last July a scientific study on the same topic was published on Biomedicine and Pharmacotherapy review; the study showed extremely interesting benefits of RIBODIET® in alleviating memory decline, neuroinflammation and oxidative stress.
Alzheimer’s disease is one of the most common form of dementia, characterized by the deposition of extracellular amyloid-β (Aβ) peptides in the brain. The neuronal death, that characterizes this neurodegenerative disorder, causes irreversible cognitive impairment and behavioral alteration.
The option of natural-derived products and nutraceuticals is scientifically solid and to be considered for a future medical option in industrialized countries. Natural products are not an alternative to drugs but, on the contrary, can be helpful to complement the pharmacological therapy and prevent the onset of chronic diseases.
In this context, has been showed that Ribonucleotides are able to improve the clinical outcomes in immunosuppressive and inflammatory-based diseases.
A recent study evaluated the effects of a ribonucleotides-based ingredient (Ribodiet®) in a non-genetic mouse model of AD. Given the strict involvement of nucleosides and nucleotides on neuronal and cognitive functions, the team of the study decided to examine whether a ribonucleotides-based ingredient could ameliorate Aβ‐induced neuro-inflammation and oxidative stress.